By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Arrowhead Pharmaceuticals (Formerly Known As Arrowhead Research Corporation) 

1118 East Green Street

Pasadena  California  91106  U.S.A.
Phone: 626-792-5549 Fax: 626-792-5554


SEARCH JOBS

Arrowhead Research Corporation is a biopharmaceutical company developing targeted RNAi therapeutics. The company is leveraging its proprietary drug delivery technologies to develop targeted drugs based on the RNA interference mechanism that efficiently silence disease-causing genes. Arrowhead technologies also enable partners to create peptide-drug conjugates that specifically home to cell types of interest while sparing off-target tissues. Arrowhead’s pipeline includes clinical programs in chronic hepatitis B virus and obesity and partner-based programs in oncology.


Key Statistics


Email: info@arrowres.com
Ownership: Public

Web Site: Arrowhead Pharma
Employees:
Symbol: ARWR
 



Industry
Medical Device






Company News
SoCal's Arrowhead Pharma (ARWR) Just Snagged a $673.5 Million Heart Deal With Amgen (AMGN) 9/29/2016 6:04:05 AM
How Ionis Pharma (IONS) is Beating the Pants Off of Competitors Like Alnylam (ALNY), Arrowhead Pharma (ARWR) and Moderna 9/20/2016 6:51:59 AM
Arrowhead Pharma (ARWR) Doses First Patient With Hepatitis B In Multiple Ascending Dose Portion Of Phase I/II Study Of ARC-521 9/7/2016 1:06:30 PM
Arrowhead Pharma (ARWR) Initiates Phase II Study Of ARC-AAT 9/6/2016 11:23:46 AM
Arrowhead Pharma (ARWR) Closes $45 Million Private Offering 8/12/2016 8:35:19 AM
Arrowhead Pharma (ARWR) Reports Fiscal 2016 Third Quarter Results 8/10/2016 11:04:21 AM
Arrowhead Pharma (ARWR) Prices $45 Million Private Offering 8/9/2016 7:13:36 AM
Arrowhead Pharma (ARWR) To Webcast Fiscal 2016 Third Quarter Results 8/2/2016 11:37:04 AM
Arrowhead Pharma (ARWR) To Present At Cantor Fitzgerald’s 2nd Annual Healthcare Conference 7/6/2016 9:13:21 AM
Arrowhead Pharma (ARWR) Initiates Phase I/II Single And Multiple Dose Study Of Hepatitis B Candidate ARC-521 6/9/2016 11:04:20 AM
12345678910...
//-->